After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma and submitted it to the Institute.

The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.

The reanalysis performed by the Assessment Group has been released to consultees and commentators. The appeal period for this appraisal has been extended to 5pm on 31 May 2006.